Baird Medical Wins "Most Valuable Investment Award" for AI Tumor Ablation Surgical Robot
Baird Medical (NASDAQ: BDMD) has received the prestigious 'Most Valuable Investment Award' at the 10th China Medical Industry Innovation Competition for its innovative AI Tumor Ablation Surgical Robot.
The competition, which showcases breakthrough medical technologies with high investment potential, recognized Baird Medical's leadership in AI-driven tumor ablation technology. The company's surgical robot is designed to enhance precision, automation, and real-time decision-making in microwave ablation (MWA), with the goal of transforming interventional oncology.
Chairwoman Haimei Wu emphasized the company's commitment to advancing AI-powered surgical solutions, expressing confidence that their innovation will establish new standards in tumor ablation and improve patient outcomes globally. Baird Medical continues to focus on accelerating the development and commercialization of this groundbreaking technology.
Baird Medical (NASDAQ: BDMD) ha ricevuto il prestigioso 'Premio per il Miglior Investimento' alla 10ª Competizione per l'Innovazione nell'Industria Medica in Cina per il suo innovativo Robot Chirurgico per Ablazione Tumorale AI.
La competizione, che mette in mostra tecnologie mediche rivoluzionarie con un alto potenziale di investimento, ha riconosciuto la leadership di Baird Medical nella tecnologia di ablazione tumorale guidata dall'AI. Il robot chirurgico dell'azienda è progettato per migliorare la precisione, l'automazione e il processo decisionale in tempo reale nell'ablazione a microonde (MWA), con l'obiettivo di trasformare l'oncologia interventistica.
La presidente Haimei Wu ha sottolineato l'impegno dell'azienda nel promuovere soluzioni chirurgiche potenziate dall'AI, esprimendo fiducia che la loro innovazione stabilirà nuovi standard nell'ablazione tumorale e migliorerà gli esiti per i pazienti a livello globale. Baird Medical continua a concentrarsi sull'accelerazione dello sviluppo e della commercializzazione di questa tecnologia rivoluzionaria.
Baird Medical (NASDAQ: BDMD) ha recibido el prestigioso 'Premio a la Inversión Más Valiosa' en la 10ª Competencia de Innovación de la Industria Médica de China por su innovador Robot Quirúrgico de Ablación Tumoral AI.
La competencia, que exhibe tecnologías médicas innovadoras con alto potencial de inversión, reconoció el liderazgo de Baird Medical en la tecnología de ablación de tumores impulsada por AI. El robot quirúrgico de la empresa está diseñado para mejorar la precisión, la automatización y la toma de decisiones en tiempo real en la ablación por microondas (MWA), con el objetivo de transformar la oncología intervencionista.
La presidenta Haimei Wu enfatizó el compromiso de la empresa de avanzar en soluciones quirúrgicas impulsadas por AI, expresando confianza en que su innovación establecerá nuevos estándares en la ablación tumoral y mejorará los resultados para los pacientes a nivel mundial. Baird Medical continúa enfocándose en acelerar el desarrollo y la comercialización de esta tecnología innovadora.
베어드 메디컬 (NASDAQ: BDMD)는 10회 중국 의료 산업 혁신 대회에서 혁신적인 AI 종양 절제 수술 로봇으로 '가장 가치 있는 투자상'을 수상했습니다.
이 대회는 높은 투자 잠재력을 가진 혁신적인 의료 기술을 선보이며, 베어드 메디컬의 AI 기반 종양 절제 기술에 대한 리더십을 인정했습니다. 회사의 수술 로봇은 마이크로웨이브 절제(MWA)에서 정밀성, 자동화 및 실시간 의사 결정을 향상시키기 위해 설계되었으며, 개입 종양학을 혁신하는 것을 목표로 하고 있습니다.
회장 하이메이 우는 AI 기반 수술 솔루션의 발전에 대한 회사의 의지를 강조하며, 그들의 혁신이 종양 절제의 새로운 기준을 세우고 전 세계적으로 환자 결과를 개선할 것이라는 확신을 표현했습니다. 베어드 메디컬은 이 혁신적인 기술의 개발 및 상용화를 가속화하는 데 계속 집중하고 있습니다.
Baird Medical (NASDAQ: BDMD) a reçu le prestigieux 'Prix d'Investissement le Plus Précieux' lors de la 10e Compétition d'Innovation de l'Industrie Médicale en Chine pour son innovant Robot Chirurgical d'Ablation Tumorale AI.
La compétition, qui met en avant des technologies médicales révolutionnaires avec un fort potentiel d'investissement, a reconnu le leadership de Baird Medical dans la technologie d'ablation tumorale pilotée par l'IA. Le robot chirurgical de l'entreprise est conçu pour améliorer la précision, l'automatisation et la prise de décision en temps réel dans l'ablation par micro-ondes (MWA), avec pour objectif de transformer l'oncologie interventionnelle.
La présidente Haimei Wu a souligné l'engagement de l'entreprise à faire progresser des solutions chirurgicales alimentées par l'IA, exprimant sa confiance que leur innovation établira de nouveaux standards dans l'ablation tumorale et améliorera les résultats pour les patients à l'échelle mondiale. Baird Medical continue de se concentrer sur l'accélération du développement et de la commercialisation de cette technologie révolutionnaire.
Baird Medical (NASDAQ: BDMD) hat den prestigeträchtigen 'Most Valuable Investment Award' beim 10. China Medical Industry Innovation Competition für seinen innovativen AI Tumor Ablation Surgical Robot erhalten.
Der Wettbewerb, der bahnbrechende Medizintechnologien mit hohem Investitionspotenzial präsentiert, erkannte die Führungsrolle von Baird Medical in der KI-gesteuerten Tumorablationstechnologie an. Der chirurgische Roboter des Unternehmens ist darauf ausgelegt, die Präzision, Automatisierung und Entscheidungsfindung in Echtzeit bei der Mikrowellenablation (MWA) zu verbessern, mit dem Ziel, die interventionelle Onkologie zu transformieren.
Vorsitzende Haimei Wu betonte das Engagement des Unternehmens für die Weiterentwicklung KI-gestützter chirurgischer Lösungen und äußerte die Zuversicht, dass ihre Innovation neue Standards in der Tumorablation setzen und die Patientenergebnisse weltweit verbessern wird. Baird Medical konzentriert sich weiterhin darauf, die Entwicklung und Kommerzialisierung dieser bahnbrechenden Technologie zu beschleunigen.
- None.
- None.
The China Medical Industry Innovation Competition is a premier industry event recognizing cutting-edge medical technologies with high investment potential. The competition highlights breakthrough innovations poised to transform healthcare, with a focus on advancing medical science and improving patient outcomes. This award underscores Baird Medical's leadership in AI-driven tumor ablation technology. The AI Tumor Ablation Surgical Robot is designed to enhance precision, automation, and real-time decision-making in microwave ablation (MWA), aiming to transform interventional oncology.
"This recognition reaffirms our commitment to advancing AI-powered surgical solutions," said Haimei Wu, Chairwoman of Baird Medical. "We believe our innovation will set new standards in tumor ablation, improving patient outcomes globally."
Baird Medical remains dedicated to accelerating the development and commercialization of its AI Tumor Ablation Surgical Robot, reinforcing its position in minimally invasive technology.
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of AI-powered surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company's technological roadmap will fully integrate breakthrough innovations from the open-source AI community—leveraging cutting-edge inference models such as Deepseek and Grok3, while fostering strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical has deployed its solutions in over 30 prestigious hospitals and clinics across
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in
The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-wins-most-valuable-investment-award-for-ai-tumor-ablation-surgical-robot-302408896.html
SOURCE BDMD
FAQ
What award did Baird Medical (BDMD) win at the China Medical Industry Innovation Competition?
What is the main purpose of Baird Medical's AI Tumor Ablation Surgical Robot?
How will Baird Medical's AI surgical robot impact patient care?
What are Baird Medical's (BDMD) future plans for their AI Tumor Ablation Surgical Robot?
When did Baird Medical (BDMD) receive the Most Valuable Investment Award?
